key: cord-0907388-zosxc56l authors: Zhou, Bing; Song, Shuo; Guo, Huimin; Zhou, Xinrong; Fan, Qing; Liu, Weilong; Cheng, Lin; Ge, Xiangyang; Ju, Bin; Zhang, Zheng title: A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS‐CoV‐2 variants including BA.1 and BA.2 in vaccinated mice date: 2022-05-06 journal: J Med Virol DOI: 10.1002/jmv.27811 sha: 6a2ce9f6393152521c848f0e3d1311d651ba77be doc_id: 907388 cord_uid: zosxc56l The SARS‐CoV‐2 vaccines have been widely used to build an immunologic barrier in the population against the COVID‐19 pandemic. However, a newly emerging Omicron variant, including BA.1, BA.1.1, BA.2, and BA.3 sublineages, largely escaped the neutralization of existing neutralizing antibodies (nAbs), even those elicited by three doses of vaccines. Here, we used the Omicron BA.1 RBD as a fourth dose of vaccine to induce potent Omicron‐specific nAbs and evaluated the broadly neutralizing activities against SARS‐CoV‐2 variants. The BA.1‐based vaccine was indeed prone to induce a strain‐specific antibody response substantially cross‐reactive with BA.2 sublineage, and yet triggered broad neutralization against SARS‐CoV‐2 variants when it was used in the sequential immunization with WT and other variant vaccines. These results demonstrated that the booster of Omicron RBD vaccine could be a rational strategy to enhance the broadly nAb response. As of March 2022, over 64% of the world population has received at least one dose of SARS-CoV-2 vaccine, 1 contributing to an immunologic barrier against the COVID-19 pandemic. However, with the waning of the titers in neutralizing antibodies (nAbs) and the emerging variants of SARS-CoV-2, the protective efficacies of various vaccines were significantly decreased. 2, 3 Although several studies showed that further booster vaccination induced potent and broad nAbs against Beta and Delta variants, the newly emerging variant Omicron, including the sublineages of BA.1, BA.1.1, BA.2, and BA.3, largely escaped the neutralization of numerous existing nAbs, even those elicited by three doses of vaccines. [4] [5] [6] [7] [8] [9] Therefore, it seems that a fourth dose of vaccine may be urgently needed to combat Omicron, and the situation highlights the importance of studies on the necessity of replacing the original wild-type (WT) virus or sequences with variants, especially Omicron. Omicron BA.1 and BA.2 harbor an unprecedented number of mutations in the spike protein, especially 15 and 16 of which appear in the receptor-binding domain (RBD), respectively, including 12 common mutations shared. 10, 11 The variants have been confirmed to have the strongest resistance to neutralization of serum nAbs elicited by natural WT-virus infection or vaccination based on the original virus sequence. 6, 8, 11 It is particularly concerning that Omicron also causes widespread antibody evasion, leading to the failure in neutralization by convalescent serum infected with a range of SARS-CoV-2 variants including Alpha, Beta, Gamma, and Delta. 12 These results indicate that Omicron has a distinctive immunogenicity compared with previous variants. On the other hand, several studies showed that the infection with Omicron variant or targeting vaccination induced a relatively strain-specific antibody response with potent neutralizing activity against Omicron but limited crossimmunity to other variants. 13, 14 Overall, to combat Omicron, it seems that another booster shot targeting Omicron should be taken into consideration, following the currently available immunization strategies to enhance the cross antibody titers. In this study, we used the Omicron BA.1 RBD as a fourth dose of Previously, we performed a series of sequential immunization with WT, Beta, or Delta RBD vaccine and inactivated vaccines in mice. Heterologous booster strategies are powerful enough to induce potent and broad neutralization against variants. 15 Here, on the basis of three doses of vaccines, we further explore the enhancing effect of Omicron BA.1 RBD in the titers of nAbs. As shown in Figure 1A Then the results were acquired by the pseudovirus-based neutralization assay (Supporting Information: Figure S1 and Table S1 ). Figure 2 ). By contrast, the neutralizing activities against other pseudoviruses including WT, Beta, and Delta variants were also increased to some extent, whose fold changes ranged from 1.8-to 5.6-fold, but not as significant as that against To compare the immune effects of different immunization strategies more clearly, we rearranged these neutralization results by different groups. As shown in Figure 3 Table S1 ). Our study has two limitations. First, due to the limited number of mice, we did not make a head-to-head comparison of the fourth dose 18 In a larger study, the researchers revealed the effectiveness of a fourth dose of BNT162b2 vaccine against Omicron based on the data of more than one-million persons who were 60 years of age or older in Israel. The rates of confirmed SARS-CoV-2 infection and severe COVID-19 were both lower than those after only three doses during the Omicron-dominated period. 19 However, a recent study raised the concern of this homologous booster immunization with the original WT virus sequence. Wang et al. stated that the peak level of RBD-nAbs elicited by a fourth dose of homologous SARS-CoV-2 inactivated vaccine was inferior to that induced by the former three doses and proposed that the nextgeneration vaccine carrying epitopes of variants would be a future direction for the booster vaccination. 20 Given the increased prevalence of Omicron BA.2 in many regions of the world, BA.2-based vaccines seem to be more appropriate to be adopted as booster vaccines. However, our results showed that the F I G U R E 2 Neutralization titers of vaccine-elicited mouse sera against SARS-CoV-2 WT and variants including Beta, Delta, Omicron BA.1 and BA.2. The data are shown for different pseudoviruses. The geometric mean titers (GMTs) and fold changes of serum nAbs between post (D230) and before (D223) the fourth vaccination are calculated and shown on the top. The symbols represent individual mice. Statistical analysis was performed with paired t-tests using GraphPad Prism 8.0 software. *p < 0.05; **p < 0.01. "X" indicates fold change. Omicron BA.1-based vaccine was prone to induce a strain-specific antibody response substantially cross-reactive with BA. COVID-19) vaccinations Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3 Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Neutralization titers of vaccine-elicited mouse sera against SARS-CoV-2 WT and variants including Beta, Delta, Omicron BA.1, and BA.2. The data are shown for different groups. The GMTs are calculated and shown on the top of each column. The fold changes in GMTs were compared between Omicron BA.1 and WT, Beta, Delta, BA.2, respectively, and written at the bottom or top. The error bars are SDs and the symbols represent individual mice Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies Neutralization of the SARS-CoV-2 1 and BA.2 variants Antibody resistance of SARS-CoV-2 1.1, BA.2 and BA.3 sub-lineages Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Antibody evasion properties of SARS-CoV-2 Omicron sublineages SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron Efficacy of a Fourth Dose of Covid-19 mRNA vaccine against Omicron Protection by a fourth dose of BNT162b2 against Omicron in Israel Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the receptor binding domain A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice This study was funded by the National Science Fund for Distinguished Young Scholars (82025022), the National Natural Science The authors declare no conflicts of interest. We are happy to share reagents and information in this study upon request. All animal experiments in mice were approved by the Ethics Committee of Shenzhen Third People's Hospital, China. All procedures were conducted in accordance with animal ethics guidelines and approved protocols to minimize suffering during vaccination and blood collection.